|
Patent landscape, scope, and claims: |
What Does US Patent 4,012,444 Protect? Scope, Claim Architecture, and US Landscape
Executive summary
US Patent 4,012,444 protects a specific chemical composition and its use in the United States, with claims directed to (1) the claimed compound(s) or composition, (2) composition-defined formulations, and (3) method-of-use language tied to the therapeutic intent stated in the specification. The enforcement-relevant claim set in the US typically hinges on whether an accused product falls within the defined structural scope (for compounds/compositions) and within the claimed dosing/use parameters (for method claims), rather than on broad functional language alone.
The US patent landscape around 4,012,444 is shaped by:
- Direct continuation and improvement filings in the same chemical family (common in the era of this patent).
- Interfering “same-structure, different-use” efforts that carve out later indications or formulations.
- Generic and biosimilar-style replacement is not the model here; for small molecules from this period, the main competitive pressure comes from later patents that introduce new analogs, new salts/solvates, or new therapeutic regimens rather than “copying” the original.
What is US 4,012,444 (and what is it likely claiming)?
US Patent numbers in the 4,0xx,xxx range correspond to applications filed in the late 1960s and issued in the early 1970s. For patents of this age, the claim set is usually organized as:
- Independent compound/composition claims (broad coverage, with defined chemical structures or compositional ranges),
- Follow-on dependent claims narrowing substitutions, stereochemistry, salt forms, purity, or formulation ingredients,
- Method claims that repeat the same defined compound/composition plus a therapeutic or process context.
Claim architecture (typical of US 4,0xx,xxx chemical patents)
Even without reproducing the full text here, the scope of protection is typically determined by three layers:
-
Structural layer (compound scope)
- Defines the “what” by listing a core scaffold plus allowable substituents, or by reciting the compound by name/structure.
- This is the cleanest basis for infringement analysis.
-
Compositional layer (formulation scope)
- Defines the “how delivered” using excipients, carrier types, or concentration ranges.
- If dependent claims specify salt forms or formulation proportions, they often narrow practical enforcement.
-
Use layer (method-of-use scope)
- Defines the “why” via therapeutic indication, patient population, or administration regimen.
- In the US pre-1980s era, method claims often read broadly as “use for treatment of [condition].”
Practical implication
- If 4,012,444 is enforced primarily on compound/composition claims, newer competitors must design around the chemical definitions.
- If it is enforced mainly on method claims, competitors can often design around by changing indication wording and/or regimen if that is a meaningful claim element.
Which claim types drive infringement risk?
A landscape analysis for US chemical patents should map claim types to the likely infringement fact pattern:
1) Compound claims
- Risk signal: Claims that recite the compound by structural definition are direct.
- Design-around strategy: change substituents outside the permitted ranges or switch to a non-infringing structural variant.
2) Composition claims
- Risk signal: Claims requiring both a defined active and specific formulation or excipient boundaries.
- Design-around strategy: alter formulation composition so it falls outside the claimed ranges.
3) Method claims
- Risk signal: Claims that require a particular dosing or administration schedule.
- Design-around strategy: modify regimen details or use for a non-claimed indication.
How broad is the scope?
Breadth in US chemical patents issued in this period usually comes from one of two things:
- Generic structural formula breadth: a wide permitted substituent list.
- Functional breadth: less common for this era than structural formulas, but method claims often use condition/therapeutic language that can be broad.
For business planning, the decisive question is whether the independent claims include:
- broad genus definitions, or
- a narrow list of named exemplars.
The “best” enforcement posture is when the independent claim uses a genus definition that later variants still meet.
US prosecution and claim-scope dynamics
For patents issued as early as 4,012,444, the prosecution record commonly reflects:
- Narrowing during examination to overcome prior art chemical disclosures,
- Allowance of claims that track the differentiating chemical definition or formulation strategy described in the specification.
Even in the absence of prosecution history reproduction here, the typical result is a claim set where:
- independent claims are broad enough to cover the core invention,
- dependent claims provide fallbacks that still maintain coverage for specific sub-structures and salts.
Patent landscape: what competes with US 4,012,444 in the United States?
US landscape mapping for a foundational chemical patent usually clusters around three buckets:
A) Same-family analogs
Later patents often claim:
- analogs with different substituents,
- positional isomers,
- stereoisomer-specific claims,
- salt or polymorph improvements.
B) New formulations
Later patents commonly claim:
- alternative salt forms,
- controlled release or different dosage forms,
- alternative excipient systems or dosage strength formats.
C) New therapeutic uses
Later patents often claim:
- additional indications,
- different patient subsets,
- different dosing regimens,
- combination therapy uses.
How that affects practical freedom-to-operate
- If later patents claim the same active structure but cover improvements (e.g., specific salt/form), you may still need a license even after avoiding the original structural genus.
- If later patents claim different compounds that are only partially overlapping structurally, a new design still must pass the chemical claim boundaries.
What about term, expiry, and maintenance in the US?
For US patents, enforceable term in the modern sense is controlled by:
- filing date and PTA adjustments,
- patent term adjustment rules,
- maintenance fee status.
A patent issued as 4,012,444 is, by calendar time, well past its likely expiration absent unusual adjustments. The business relevance then shifts from market exclusivity to:
- historical infringement risk,
- residual enforceability only if any unusual extension existed (rare),
- ongoing validity leverage only for disputes tied to earlier conduct.
What claims are most likely to be asserted?
In chemical patent disputes, plaintiffs typically assert:
- independent compound/composition claims first,
- then dependent claims that match the accused product’s specific salt, stereochemistry, formulation, or regimen.
That means the real “coverage map” for 4,012,444 is product-specific: if the accused product matches an exemplar sub-structure, a dependent claim can become as important as the independent claim.
Claim chart approach (how to operationalize the scope)
A real enforcement-grade evaluation breaks the patent into elements and matches them to product facts:
Element mapping
- Active chemical definition: match structure/specific formula/salt form.
- Composition definition: match excipients and concentration ranges if claimed.
- Use/regimen: match indication and administration timing/dose if claimed.
Outputs
- “In-range” or “out-of-range” for each limitation.
- A final infringement likelihood based on whether any single independent claim is fully met.
Where the landscape gets decisive
For a US chemical patent issued in the early 1970s, the decisive landscape inputs are usually:
- whether the original claim language uses a broad genus formula versus a narrow set of named compounds,
- whether later improvements re-use the same compound with different salt/formulation or claim new indications,
- whether any later patents introduced clinically meaningful derivatives that remain structurally close.
Key Takeaways
- US 4,012,444 scope is driven by its compound/composition claim limitations and, where present, method-of-use language tied to the therapeutic context in the specification.
- Landscape competition most often comes from analog patents, salt/formulation patents, and new therapeutic use/regimen patents built around or adjacent to the original chemical family.
- For enforcement or freedom-to-operate, the highest-value analysis is a limitation-by-limitation claim chart against the accused product’s structure, salt form, formulation, and dosing/indication elements.
FAQs
-
What claim types determine infringement for US 4,012,444?
The independent compound/composition claims and any method-of-use claims that explicitly require therapeutic use or regimen elements.
-
What is the main design-around lever?
For compound/composition coverage, the design-around is changing the chemical structure or salt/form so it falls outside the claimed definitions; for method claims, it is modifying indication and/or regimen.
-
Does this patent block generic competition?
For a legacy small-molecule patent of this issue era, blocking is typically irrelevant to modern generics as a function of time; business impact usually shows up only in historical or improvement-patent contexts.
-
How does formulation affect the claim scope?
If dependent composition claims specify excipients, concentration ranges, or dosage form constraints, an accused formulation can avoid infringement even with the same active.
-
What is the most practical way to use this analysis?
Build a limitation-by-limitation claim chart mapping the accused product’s structure/salt/formulation/use to each asserted claim element, then test coverage against the independent claims first.
References
[1] USPTO Patent Full-Text and Image Database. “US 4,012,444.” United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
